Clinical-stage biopharmaceutical company Nuvalent, Inc. (Nasdaq:NUVL) announced on Monday the initiation of HEROEX-1, a Phase 1a/1b clinical trial for NVL-330.
NVL-330 is a novel HER2-selective inhibitor targeting HER2-altered non-small cell lung cancer (NSCLC) in pre-treated patients. HER2 alterations, including exon 20 mutations, are key oncogenic drivers in NSCLC with no approved TKIs for this patient population. NVL-330 aims to address this by maintaining activity against HER2 exon 20 mutations, limiting EGFR-related toxicities, and penetrating the brain to tackle metastases.
HEROEX-1 will evaluate NVL-330's safety, tolerability, recommended Phase 2 dose, pharmacokinetic profile and preliminary anti-tumor activity.
This trial involves a multicenter, open-label, dose-escalation and expansion study design. NVL-330's differentiated preclinical profile supports its potential efficacy in this clinical investigation.
Sanofi commits USD18m to boost diversity in clinical studies
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
Saniona reaches milestone in Boehringer Ingelheim partnership
Lipella granted patent for innovative drug delivery technology
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
PharmAbcine's PMC-403 Phase one clinical trial single ascending dose cohort receives safety approval
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline